Core Viewpoint - The company Zhongguancun (000931.SZ) announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., has received an acceptance notice from the National Medical Products Administration for the marketing authorization application of Sitagliptin Metformin Tablets (II) [1] Group 1 - Duoduo Pharmaceutical's Sitagliptin Metformin Tablets (II) contain 50mg of Sitagliptin (as Sitagliptin phosphate) and 850mg of Metformin hydrochloride per tablet [1] - The product was initiated for development in 2023 and is indicated for use in combination with diet and exercise to treat type 2 diabetes patients whose blood sugar is not adequately controlled on Metformin monotherapy or who are currently receiving dual therapy [1]

多多药业西格列汀二甲双胍片(II)(规格：每片含磷酸西格列汀50mg(以西格列汀计)和盐酸二甲双胍 850mg)于2023年立项开发，其适应症为：本品配合饮食和运动治疗，用于经二甲双胍单药治疗血糖仍 控制不佳或正在接受二者联合治疗的2型糖尿病患者。 智通财经APP讯，中关村(000931.SZ)发布公告，公司下属公司多多药业有限公司(以下简称：多多药业) 于近日收到国家药品监督管理局(以下简称：国家药监局)签发的《受理通知书》，西格列汀二甲双胍片 (II)(规格：每片含磷酸西格列汀50mg(以西格列汀计)和盐酸二甲双胍850mg)上市许可申请获得受理。 ...